ANMAT prohibits the use and sale of an anticancer drug

By the 6769/2019 provision of the Official Journal, it is activated on any batch of the product "Keytruda, Pembrolizumab 100 mg / 4 ml, solution for infusion with 1 vial with 4 ml of solution for injection", having the following characteristics: secondary without traceability label, security seal violated and main container (bottle) with blue cap bearing the inscription "FLIP-OFF" in relief.

According to the National Cancer Institute of the United States, Keytruda is a medicine used to "treat renal cell carcinoma (a type of kidney cancer) advanced stage that has not yet been treated. "In addition, the entity notes, it is used in certain types of lung cancer, cervical cancer, stomach cancer, Hodgkin's lymphoma and melanoma, among others.